The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
August 25th 2025
Evolocumab is now indicated for adults at increased risk for major adverse cardiovascular events (MACE).
Drug Receives FDA's Breakthrough Therapy Designation for Treating Individuals with Schizophrenia
May 11th 2019The designation is intended to expedite the development and review of drugs for serious or life-threatening conditions when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on one or more clinically significant endpoints.
Read More
Patient Selection for AML Therapies
May 9th 2019Bernard Marini, PharmD, BCOP, an Inpatient Hematology Specialist at the University of Michigan, discusses the selection of therapies for patients with acute myeloid leukemia, during the Hematology/Oncology Pharmacy Association's 2019 annual meeting in Fort Worth, Texas.
Watch
Combination Nasal Spray Demonstrates Results in Treating Children with Seasonal Allergic Rhinitis
May 8th 2019Positive results were collected from a Phase 3 study of an investigational fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis (SAR), according to Glenmark Pharmaceuticals.
Read More
Benefits of Implementing Pharmacist Services
May 8th 2019Jaron Stout, PharmD, owner, consulting pharmacist, Collaborative Pharmacy Consultants, discusses the benefits of pharmacist services and a personal success story. This video was filmed at the American Society of Consultant Pharmacists' 2019 Forum in Washington, DC.
Watch
Risk Reduction for Colon Cancer
May 7th 2019Amber Draper, PharmD, BCOP, clinical pharmacist, Winship Cancer Institute in Georgia discusses educating patients about lifestyle and dietary factors that increase risk of colon cancer. This video was filmed at the 2019 Hematology/Oncology Pharmacy Association Annual Conference in Fort Worth, Texas.
Watch
Combination Drug for Adults with T2D is Granted FDA Approval
May 6th 2019Dapagliflozin is a selective sodium‑glucose cotransporter-2 (SGLT-2) inhibitor that is combined with a dipeptidyl peptidase‑4 (DPP‑4) inhibitor, saxagliptin; and metformin hydrochloride extended release.
Read More
Collaborative Practice Agreements
May 5th 2019Jaron Stout, PharmD, owner, consulting pharmacist, Collaborative Pharmacy Consultants, discusses collaborative practice agreements and how they vary between states. This video was filmed at the American Society of Consultant Pharmacists' 2019 Forum in Washington, DC.
Read More
Trellegy Ellipta Hits Phase 3 Asthma Marks, Eyes New Indication
May 5th 2019Pivotal phase 3 trial results show benefits for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy Ellipta) in patients with uncontrolled asthma compared with standard FF/VI (Breo Ellipta) therapy.
Read More
Beta Interferon Treatment Shown to Improve Long-Term Survival in Patients with MS
May 4th 2019In the first and largest study of its kind, researchers from the University of British Columbia (UBC) and Vancouver Coastal Health Research Institute aimed to assess mortality associated with beta interferons for the treatment of MS.
Read More